The Key Players in Global Glioblastoma Multiforme Therapeutics Market 2015-2019

Wednesday 29 July 2015, Amsterdam

Market Research Report Press Release The report recognizes the following companies as the key players in the Global Glioblastoma Multiforme Therapeutics Market: Arbor Pharmaceuticals LLC, Bristol-Myers Squibb Co., Eisai Co. Ltd., F. Hoffmann-La Roche Ltd. And Merck & Co. Ltd.

Commenting on the report, an analyst said: “The entry of novel therapeutic agents to treat glioblastoma multiforme is a major trend witnessed in the market. The drugs which are currently being used are mostly chemotherapeutic agents that are usually toxic to the cells of the body. These drugs are known to also harm the non-cancerous cells besides destroying the malignant cells.”

According to the report, the market is expected to grow because of the presence of significant unmet need. This presents an opportunity to the drug makers to develop a therapy to treat glioblastoma multiforme with better efficacy and safety parameters. This in turn will reduce the rate of treatment withdrawal by patients, which would be a positive indicator of growth to the market.

Further, the report states that market growth may be hampered because of use of off-label and generic drugs over the branded drugs available in the market. Most of the branded drugs have either lost their patent or will lose their patent during the forecast period.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Global Glioblastoma Multiforme Therapeutics Market 2015-2019

Global Glioblastoma Multiforme Therapeutics Market 2015-2019

Publish date : July 2015
Report code : ASDR-210886
Pages : 81

ASDReports.com Media contact: S. Koopman - Marketing and Communications

ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E : stefan.koopman@asdreports.com

 back to News